GSK, Gilead HIV Fixed-Dose Combination Drugs Clear FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The approvals of Gilead’s Truvada and GSK’s Epzicom were announced publicly by FDA Acting Commissioner Crawford during a Washington, D.C. luncheon speech. Gilead is shipping Truvada to wholesalers this week. Two month supplies of Epzicom will be available free to patients through participating physicians for a limited time.
You may also be interested in...
Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says
Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.
Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says
Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.
Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”